ÂÜÀòÂÒÂ×

Richard Schneiderman is an accomplished scientist with a broad background in biomedical research and drug development. Currently serving as a Principal Scientist at Acorda Therapeutics, Inc. and a Scientific Review Officer at the National Institutes of Health since August 2018, Richard has previously held leadership roles including Director of Cardiovascular Research at the Danbury Hospital Biomedical Research Institute. This facility focuses on cancer, cardiovascular, and Lyme disease research. Richard's extensive experience includes a decade as Principal Scientist at Boehringer Ingelheim Pharmaceuticals, initial scientific positions at Baxter Healthcare and Genetic Therapy Inc., and a postdoctoral role at the Laboratory of Cell Biology, NIMH, NIH. Richard earned a Ph.D. in Immunology from the University of Illinois College of Medicine between 1982 and 1989.